Objective
The purpose of this study was to compare clinical characteristics and survival between
patients with stage I epithelial ovarian cancer and fallopian tube cancer.
Study Design
We identified women with stage I epithelial ovarian cancer and fallopian tube cancer
who underwent treatment from 2000-2010. Correlation between categoric variables was
assessed with χ2 test. The Kaplan-Meier survival analysis was used to generate overall survival data.
Factors predictive of outcome were compared with the use of the log-rank test and
Cox proportional hazards model.
Results
The study group consisted of 385 women with epithelial ovarian cancer and 43 women
with fallopian tube cancer. Patients with fallopian tube cancer had a higher rate
of stage IA disease (65% vs 48%; P = .02) and grade 3 tumors (60.4% vs 30.9%; P < .001). Patients with fallopian tube cancer had a significantly higher rate of breast
cancer (25.6% vs 5.7%; P < .001) and BRCA 1 mutations (45.8% vs 9.1%; P < .001). There was no difference in the rates of platinum-based and paclitaxel chemotherapy
between the groups. Women with fallopian tube cancer were more likely to have received
≥6 cycles of chemotherapy (58.1% vs 44.1%; P = .02). The 5-year disease-free survival rates were 100% in women with fallopian
tube cancer and 93% in patients with epithelial ovarian cancer (P = .04). The 5-year overall survival rates were 100% and 95% for fallopian tube cancer
and epithelial ovarian cancer, respectively (P = .7).
Conclusion
We found a higher rate of stage IA, grade 3, and serous carcinoma in fallopian tube
cancer. Women with fallopian tube cancer had a higher rate of breast cancer. There
was no difference in overall survival between the groups.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Obstetrics & GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer of the ovary.N Engl J Med. 2004; 351: 2519-2529
- Ovarian cancer.Lancet. 2009; 374: 1371-1382
- Systematic review of adjuvant care for women with stage I ovarian carcinoma.Cancer. 2004; 101: 1926-1935
- Fallopian tube carcinoma: a review.The Oncologist. 2006; 11: 902-912
- Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer.Cancer. 2008; 113: 3298-3306
- Changing in definitions of clinical staging for carcinoma of the cervix and ovary.Am J Obstet Gynecol. 1987; 156: 263-264
- Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.Gynecol Oncol. 2013; 131: 46-51
- Prognostic factors in early-stage ovarian cancer.Ecancermedicalscience. 2013; 13: 325
- Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.Cancer. 2008; 112: 2202-2210
- Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.Gynecol Oncol. 2007; 107: 398-403
- Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.J Gynecol Oncol. 2011; 22: 9-17
- Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials.N Engl J Med. 1990; 322: 1021-1027
- International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.J Natl Cancer Inst. 2003; 95: 105-112
- Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2006; 102: 432-439
- Precursors to pelvic serous carcinoma and their clinical implications.Gynecol Oncol. 2009; 113: 391-396
- Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.Cochrane Database Syst Rev. 2012; 3: CD004706
- Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial.J Natl Cancer Inst. 2010; 102: 982-987
- Systematic reviews of adjuvant care for women with stage I ovarian carcinoma.Cancer. 2004; 101: 1926-1935
- Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.J Clin Oncol. 2003; 21: 4222-4227
- The incidence of primary fallopian tube cancer in the United States.Gynecol Oncol. 2007; 107: 392-397
- Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.Gynecol Oncol. 2010; 118: 299-302
- Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.Gynecol Oncol. 2013; 129: 63-68
Article Info
Publication History
Published online: December 13, 2014
Accepted:
December 11,
2014
Received in revised form:
November 7,
2014
Received:
September 11,
2014
Footnotes
Supported by the Deborah Kelly Center for Outcomes Research, Massachusetts General Hospital , Boston, MA.
The authors report no conflict of interest.
Cite this article as: Rauh-Hain JA, Foley OW, Winograd D, et al. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. Am J Obstet Gynecol 2015;212:600.e1-8.
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
